Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

To perform PCR from serum for the diagnosis of visceral leishmaniasis is convenient and much less invasive than the examination of deeper compartments such as bone marrow. We compared three -specific real-time PCRs with three different molecular targets (kinetoplast DNA, the small subunit-ribosomal RNA-(ssrRNA-)gene, the glucose-6-phosphate isomerase-(-)gene) regarding their sensitivity and specificity in human serum. Residual sera from previous diagnostic assessments at the German National Reference Center for Tropical Pathogens Bernhard Nocht Institute for Tropical Medicine Hamburg and the Swiss Tropical and Public Health Institute were used. The sensitivities of kinetoplast DNA-PCR, ssrRNA-gene PCR, and -PCR were 93.3%, 73.3%, and 33.3%, respectively, with 15 initial serum samples from visceral leishmaniasis patients, as well as 9.1%, 9.1%, and 0.0%, respectively, with 11 follow-up serum samples taken at various time points following anti-leishmanial therapy. Specificity was 100.0% in all assays as recorded with 1.137 serum samples from deployed soldiers and migrants without clinical suspicion of visceral leishmaniasis. Kinetoplast-DNA PCR from serum was confirmed as a sensitive and specific approach for the diagnosis of visceral leishmaniasis. The results also indicate the suitability of serum PCR for diagnostic follow-up after therapy, in particular regarding therapeutic failure in case of persisting positive PCR results.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8308501PMC
http://dx.doi.org/10.3390/pathogens10070826DOI Listing

Publication Analysis

Top Keywords

visceral leishmaniasis
16
serum samples
12
kinetoplast dna
8
dna small
8
serum
8
human serum
8
pcr serum
8
diagnosis visceral
8
pcr
6
comparison three
4

Similar Publications

The role of Denisovan paleohabitats in shaping modern human genetic resistance to viral, bacterial, and parasitic infections.

J Hum Evol

September 2025

Sustainability Solutions Research Lab, University of Pannonia, Egyetem utca 10, H-8200, Veszprém, Hungary. Electronic address:

Denisovans contributed notably to the genomes of present-day East and Southeast Asians. However, the relationship between the inhabited paleohabitats and the adaptive genetic traits related to infections in modern humans remains underexplored. This study uses geospatial techniques to analyze climatic factors associated with three Denisovan archaeological sites linked to nine specimens.

View Article and Find Full Text PDF

Objective: Leishmaniasis, caused by protozoan parasites of the spp., presents significant global health challenges, with visceral leishmaniasis (VL) and cutaneous leishmaniasis forms causing severe morbidity and mortality. Macrophages serve as primary host cells, where spp.

View Article and Find Full Text PDF

Leishmaniasis in the United Kingdom: Experience of a national multidisciplinary team meeting in a non-endemic setting.

Travel Med Infect Dis

September 2025

Hospital for Tropical Diseases, University College London Hospitals NHS Foundation Trust. London, UK; Clinical Research Department, London School of Hygiene and Tropical Medicine, London, UK.

Introduction: Leishmaniasis is a parasitic disease caused by protozoa of the genus Leishmania. Disease phenotypes are heterogenous, and diagnosis is frequently delayed. Treatment is often challenging, and international guidelines recommend consultation with experts.

View Article and Find Full Text PDF

Leishmaniasis, a disease caused by Leishmania parasites, poses a significant health threat globally, particularly in Latin America and Brazil. Leishmania amazonensis is an important species because it is associated with both cutaneous leishmaniasis and an atypical visceral form. Current treatments are hindered by toxicity, resistance, and high cost, driving the need for new therapeutic targets and drugs.

View Article and Find Full Text PDF

Background: Neglected tropical diseases (NTDs) are a group of 21 diseases affecting approximately 1.5 billion people globally. Significant progress has been made in their control: by March 2024, 50 countries had eliminated at least one NTD, with 13 of these countries eliminating at least two.

View Article and Find Full Text PDF